Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

957
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
957
Antibody Structure01:10

Antibody Structure

60.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization.

mAbs·2026
Same author

Surface patches induce nonspecific binding and phase separation of antibodies.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same author

Structural Considerations in Affinity Maturation of Antibody-Based Biotherapeutic Candidates.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics.

mAbs·2021
Same author

Identifying biophysical assays and <i>in silico</i> properties that enrich for slow clearance in clinical-stage therapeutic antibodies.

mAbs·2021
Same author

Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.

mAbs·2020

Related Experiment Video

Updated: Aug 22, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K

Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for

Nels Thorsteinson1, Stephen R Comeau2, Sandeep Kumar3

  • 1Scientific Services Manager, Biologics, Chemical Computing Group ULC, Montreal, QC, Canada.

Methods in Molecular Biology (Clifton, N.J.)
|November 8, 2022
PubMed
Summary

Early computational strategies significantly improve biotherapeutic drug development by predicting and mitigating risks associated with antibody candidates. This helps optimize drug leads for better developability and reduces late-stage failures.

Keywords:
AggregationAntibodyChemical degradationDevelopabilityPhysicochemical properties

More Related Videos

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.7K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.7K

Related Experiment Videos

Last Updated: Aug 22, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

18.7K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.7K

Area of Science:

  • Biopharmaceutical Development
  • Computational Chemistry
  • Drug Discovery

Background:

  • Increasing emphasis on mitigating developability risks early in biotherapeutic drug discovery.
  • Need for predictive computational strategies to reduce late-stage antibody candidate failures.

Purpose of the Study:

  • To discuss the history and application of structure-based computational methods for predicting antibody developability.
  • To demonstrate how these methods can filter and optimize antibody candidates during early development.

Main Methods:

  • Utilizing structure-based computational strategies for property prediction.
  • Modeling antibody structures from sequence data.
  • Detecting liabilities such as post-translational modifications and chemical degradation.

Main Results:

  • Demonstration of computational methods for filtering large candidate sets.
  • Optimization of lead candidates for improved developability.
  • Identification of potential risks early in the development pipeline.

Conclusions:

  • Predictive computational strategies are crucial for early risk mitigation in antibody development.
  • Structure-based methods effectively enhance the selection and optimization of developable antibody candidates.
  • Integrating these methods reduces the likelihood of late-stage failures in biotherapeutic development.